University Hospital Tuebingen
Molecular Inflammation Board at the Center for Personalized Medicine
Psoriasis (PsO)
Psoriasis Arthritis
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
Spondylarthropathies
Biologic Agent
Molecular Inflammation Board at the Center for Personalized Medicine The study objectives are: To ensure a prospective documentation of all patients who are referred to the Molecular Inflammation Board in routine clinical care To prospectively ensure the documentation of MEB patients with an emphasis to clinical outcome parameters and further response assessments (e.g. peripheral immunmonitoring, imaging parameters) To prospectively assess patient-reported outcome of MEB patients To evaluate compliance to MEB suggestions in routine clinical care
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 3000 participants |
| Official Title : | The Molecular Inflammation Board at the Centers for Personalized Medicine at the University Hospitals of Freiburg, Heidelberg, Tübingen and Ulm - A Multicenter Prospective Observational Study |
| Actual Study Start Date : | 2022-11-16 |
| Estimated Primary Completion Date : | 2032-11 |
| Estimated Study Completion Date : | 2032-11 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | ALL |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
University Hospital of Tübingen - Center for Personalized Medicine
Tübingen, Germany, 72076